Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI received intravenous (IV) vancomycin for the first two days of treatment and were then randomised to either continue to receive IV vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients have been randomised for this study.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with IV vancomycin in the treatment of cSSSI. The primary endpoint is the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcome as well as safety and tolerability.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The speed of enrolment in this Phase II trial surpassed our expectations. It again shows that an 'intravenous-to-oral' step-down therapy serves a medical need and could add significant value to intravenous iclaprim. Marketing applications for intravenous iclaprim have been filed in the U.S.A., the European Union and Canada. We will release the top-line data of this Phase II switch study in the coming months and subsequently determine the path ahead."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product can
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015  The recent flurry of PBM ... employer groups scrambling to identify a pharmacy benefit ... care plan, retail pharmacy chain, or other potentially ... purchase of Catamaran, Rite Aid,s $2 billion acquisition ... Omni-Care for $10 billion are just the latest ...
(Date:5/28/2015)... May 28, 2015 The Federal Trade ... antitrust suit charging Cephalon, Inc. with illegally blocking ... The settlement ensures that Teva Pharmaceutical Industries, Ltd., ... total of $1.2 billion available to compensate purchasers, ... because of Cephalon,s illegal conduct.  ...
(Date:5/28/2015)... , May 28, 2015 Lungpacer Medical, ... catheter-based phrenic-nerve-pacing system announced today that it will ... Conference on Thursday, June 4, 2015 in New ... 11:30 a.m. Eastern Time.   About ... a preclinical stage medical device company pioneering the ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 2FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 3
... Conn., Sept. 23, 2011 Butrans® (Buprenorphine) Transdermal System ... pain over the last 24 hours" scores compared to ... moderate-to-severe chronic low back pain , according to ... online, August issue of The Journal of Pain ...
... 2011 Take Care Health Systems, a wholly-owned subsidiary ... Sanofi US today announced the opening of a full-service ... in Bridgewater, New Jersey. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO) ... dedicated to solving health challenges, it is essential for ...
Cached Medicine Technology:Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 2Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 3Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 4Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 5Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 6Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 2Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 3Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 4Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 5
(Date:5/28/2015)... Restricting access to firearms for people who ... more clearly define alcohol misuse should be developed to ... and public policies by the UC Davis Violence Prevention ... in the peer-reviewed journal Preventive Medicine , summarizes ... misuse in association with firearm access and use, including ...
(Date:5/28/2015)... 28, 2015 AMVETS leaders this week ... winner Robert Davis of Newark, Del. AMVETS National Commander ... on winning the $10,000 sweepstakes grand prize. , AMVETS ... entries from around the country for prizes ranging from ... place on May 21 at the AMVETS National Headquarters ...
(Date:5/28/2015)... The Paw Project, an international ... intended to educate the Oregon public about the harmful ... of Market Street and Park Avenue in Salem, Oregon's ... De-clawing Cats, Raise Your Hand,” depicts a human hand ... a graphic and anatomically-correct representation of the declaw surgery ...
(Date:5/28/2015)... PA (PRWEB) May 28, 2015 The ... today announced a just launched blog series which provides ... Hosted on the “R. Bruce Dalglish” profile on ... of R. Bruce Dalglish’s corporate experience. , “Throughout ... positive workplace cultures have upon the overall success of ...
(Date:5/28/2015)... Ticket Down is a reputable source of ... Mexico and Argentina in early September. , Two of ... on the pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico ... friendly on Tuesday, September 8th at 9 p.m. The match ... world including some of the most loved players in the ...
Breaking Medicine News(10 mins):Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 2Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 3Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 4Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3
... of C.difficile’s genetic code is reported to have been ... will enable faster diagnosis and treatment of the ailment ... to the Jewish General Hospital’s Dasval. The strain has ... in Quebec. The search can now commence for the ...
... Schepens Eye Research Institute (SERI) found that increasing the ... more enjoyable to the visually impaired. // ,The ... electronic device to help millions suffering eye diseases. People ... suffering from macular degeneration, diabetic retinopathy and other causes ...
... the first to visualize a need for laboratories in the Mexican ... Sustainability Laboratory (BNSL), which extends over an area of 4000 square ... security force and deal with terrorism // with the help ... for the lab come from USA, State of New Mexico and ...
... study done by a researcher Yun Zhang at the Rockefeller ... of worms. // ,The research was mainly conducted on ... the soil and feeds on various bacteria (both harmless and ... to individual behaviors. ,The genes responsible for the ...
... Annals of Internal Medicine this week have found that ... verge of kidney failure is useless. //The study conducted ... London, Canada found that a treatment called "plasma exchange" ... ,This means that the money which is currently ...
... Wahangara, 12 year old boy from Indonesia had a tumor ... the tumor made up around 10% of his body weight.// ... at Mount Elizabeth Hospital involving different specialties. ,The ... an endemic problem in Sumba. The 7.87 inches tumor developed ...
Cached Medicine News:Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3Health News:Worms Learn To Choose Their Diet 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: